<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835367</url>
  </required_header>
  <id_info>
    <org_study_id>40013</org_study_id>
    <nct_id>NCT00835367</nct_id>
  </id_info>
  <brief_title>Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption if
      amlodipine-benzazepril 10 mg-20 mg capsules (test) versus Lotrel® (reference),administered as
      1 x 10 mg- 20 mg capsule under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Amlodipine</measure>
    <time_frame>Blood samples collected over 168 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-Inf - Amlodipine</measure>
    <time_frame>Blood samples collected over 168 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Amlodipine</measure>
    <time_frame>Blood samples collected over 168 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax - Benazepril</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-Inf - Benazepril</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Benazepril</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - Benazeprilat</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-Inf - Benazeprilat</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - Benazeprilat</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amlodipine Benazepril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrel®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine-benazepril 10 mg-20 mg capsules</intervention_name>
    <description>1 x 10-20 mg</description>
    <arm_group_label>Amlodipine Benazepril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lotrel® 10 mg-20 mg capsule</intervention_name>
    <description>1 x 10-20 mg</description>
    <arm_group_label>Lotrel®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male of non-child-bearing potential female, non-smoker, 18 years of age and older.

          -  Non-child-bearing potential female subjects is defined as follows:

          -  Post-menopausal state: absence of menses for 12 months prior to drug administration or
             hysterectomy woth bilateral oophorectomy at least 6 months prior to drug
             administration.

          -  Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at least 6
             months prior to drug administration.

          -  Capable of consent

        Exclusion Criteria:

          -  Clinically significant illnesses within 4 weeks prior to the administration of the
             study medication.

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judges clinically significant.

          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.

          -  EGC abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 100 ot over 140 nnHg, diastolic blood pressure lower than 60 or
             over 90 mmHg, or heart rate less that 60 or over 100 bpm) at screening.

          -  BMI ≥ 30.0

          -  History of significant alcohol abuse within six months prior to the screening visit or
             any indication of the regular use of more than fourteen units of alcohol per week ( 1
             Unit= 150 mL of wine, 360 mL of beer, or 45 mL ot 40% alcohol) or positive alcohol
             breath test at screening.

          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)
             within 3 months prior to the screening visit or hard drugs( such as cocaine,
             phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive
             urine drug screen at screening.

          -  History of allergic reactions to heparin, ramipril, or other ACE inhibitors, or other
             related drugs.

          -  Use of any drugs known to induce hepatic drug metabolism (examples of inducers:
             barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; examples of
             inhibitors: antidepressant (SSRI), cimetidine, diltiazem, macrolides, imidazoles,
             neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to
             administration of the study medication.

          -  Use of and investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication.

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver of kidney
             disease, or other conditions known to interfere with the absorption, distribution,
             metabolism, or excretion of the drug.

          -  Any clinically significant history or presence of clinically significant neurological,
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or
             metabolic disease.

          -  Use of prescription medication ( including hormone replacement therapy) within 14 days
             prior to administration of study medication or over-the-counter products (including
             natural food supplements, vitamins, garlic as a supplement) within 7 days prior to
             administration of study medication, except for topical products without systemic
             absorption.

          -  Difficulty to swallow study medication. Subjects who have used tobacco in any form
             within the 90 days preceding study drug administration

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             Medical Sub-Investigator, could contraindicate the subject's participation in this
             study.

          -  A depot injection or an implant of any drug within 3 months prior to administration of
             study medication.

          -  Donation of plasma (500 mL) within 30 days prior to drug administration. Donation or
             loss of whole blood (excluding the volume of blood that will be drawn during the
             screening procedures of this study) prior to administration of the study medication as
             follows:

          -  50 mL to 300 mL of whole blood within 30 days,

          -  301 mL to 500 mL of whole blood within 45 days, or

          -  more than 500 mL of whole blood within 56 days prior to drug administration.

          -  Consumption of food or beverages containing grapefruit ( e.g. fresh, canned, or
             frozen) within 7 days prior to administration of the study medication.

          -  Intolerance to venipunctures

          -  Unable to understand or unwilling to sign the Informed Consent Form.

          -  Clinically significant history of angioedema. Subjects with a clinically significant
             history or active hypotension. Subjects with a significant history of active
             neutropenia and/or agranulocytosis.

          -  Breast-feeding subject.

          -  Positive urine pregnancy test at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>May 6, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>July 6, 2009</last_update_submitted>
  <last_update_submitted_qc>July 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine Benazepril (Test) First</title>
          <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in first period followed by Lotrel® 10/20 mg capsule (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Lotrel® (Reference) First</title>
          <description>Lotrel® 10/20 mg capsule (reference) dosed in first period followed by Amlodipine Benazepril 10/20 mg capsule (test)dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amlodipine Benazepril (Test) First</title>
          <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in first period followed by Lotrel® 10/20 mg capsule (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Lotrel® (Reference) First</title>
          <description>Lotrel® 10/20 mg capsule (reference) dosed in first period followed by Amlodipine Benazepril 10/20 mg capsule (test)dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Amlodipine</title>
        <description>Bioequivalence based on Cmax - Maximum observed concentration</description>
        <time_frame>Blood samples collected over 168 hour period</time_frame>
        <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Amlodipine</title>
          <description>Bioequivalence based on Cmax - Maximum observed concentration</description>
          <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5621.36" spread="1079.24"/>
                    <measurement group_id="O2" value="5536.86" spread="1183.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>101.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.22</ci_lower_limit>
            <ci_upper_limit>105.59</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Amlodipine</title>
        <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 168 hour period</time_frame>
        <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Amlodipine</title>
          <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370735.08" spread="105920.24"/>
                    <measurement group_id="O2" value="363080.38" spread="111778.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>102.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.71</ci_lower_limit>
            <ci_upper_limit>105.44</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Amlodipine</title>
        <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
        <time_frame>Blood samples collected over 168 hour period</time_frame>
        <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Amlodipine</title>
          <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
          <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329314.07" spread="81902.24"/>
                    <measurement group_id="O2" value="322615.55" spread="88414.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>102.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.75</ci_lower_limit>
            <ci_upper_limit>105.30</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Benazepril</title>
        <description>Bioequivalence based on Cmax - Maximum observed concentration</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Benazepril</title>
          <description>Bioequivalence based on Cmax - Maximum observed concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.13" spread="30.76"/>
                    <measurement group_id="O2" value="101.55" spread="39.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>91.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>84.83</ci_lower_limit>
            <ci_upper_limit>99.32</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - Benazeprilat</title>
        <description>Cmax - Maximum observed concentration</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Benazeprilat</title>
          <description>Cmax - Maximum observed concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.79" spread="63.90"/>
                    <measurement group_id="O2" value="235.85" spread="69.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>95.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.54</ci_lower_limit>
            <ci_upper_limit>99.27</ci_upper_limit>
            <estimate_desc>Metabolite presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf - Benazeprilat</title>
        <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Benazeprilat</title>
          <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1645.73" spread="483.54"/>
                    <measurement group_id="O2" value="1631.10" spread="458.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>100.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.30</ci_lower_limit>
            <ci_upper_limit>102.30</ci_upper_limit>
            <estimate_desc>Metabolite presented for informational purposes only</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Benazepril</title>
        <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Benazepril</title>
          <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.36" spread="50.83"/>
                    <measurement group_id="O2" value="194.76" spread="47.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>102.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100.35</ci_lower_limit>
            <ci_upper_limit>105.19</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Benazepril</title>
        <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Benazepril</title>
          <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.23" spread="49.99"/>
                    <measurement group_id="O2" value="190.74" spread="46.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>102.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100.30</ci_lower_limit>
            <ci_upper_limit>105.20</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - Benazeprilat</title>
        <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test)dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Benazeprilat</title>
          <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1611.85" spread="480.27"/>
                    <measurement group_id="O2" value="1597.94" spread="458.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>100.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.25</ci_lower_limit>
            <ci_upper_limit>102.35</ci_upper_limit>
            <estimate_desc>Metabolite presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>TEVA Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

